DJS Antibodies is developing novel therapeutics to treat chronic inflammatory diseases. DJS does this through the discovery and development of novel therapeutic monoclonal antibodies against GPCRs. The company's breakthrough technology enables its to produce first-in-class antibody therapeutics to previously intractable disease targets.

Biotechnology

Health Care

Therapeutics

DJS Antibodies

Dale Starkie

Joe Illingworth

Amanda Hall

The Research and Development Team at DJS Antibodies is responsible for the discovery and optimization of innovative monoclonal antibodies targeting G protein-coupled receptors (GPCRs) to combat chronic inflammatory diseases. This team, comprised of senior scientists and research associates, conducts in-depth scientific research, develops therapeutic candidates, and facilitates preclinical testing, driving the advancement of first-in-class therapies from concept to reality.

Research and Development Team

About

Team members